Irritable bowel syndrome

Clinical Drug Investigation

Volumn 27, Issue 1, 2007, Pages 15-33

  Spinelli, Antonella ^a  

^a Policlinico di Monza   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALOSETRON; AMITRIPTYLINE; ANTIDIARRHEAL AGENT; BENZODIAZEPINE DERIVATIVE; DESIPRAMINE; DIAZEPAM; DIPHENOXYLATE; HERBACEOUS AGENT; LOPERAMIDE; OTILONIUM BROMIDE; PINAVERIUM BROMIDE; PROBIOTIC AGENT; PSYCHOTROPIC AGENT; SEROTONIN; SEROTONIN AGONIST; SPASMOLYTIC AGENT; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMEBUTINE;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ANXIETY DISORDER; CLINICAL FEATURE; CLINICAL TRIAL; CONSTIPATION; COST BENEFIT ANALYSIS; DIAGNOSTIC TEST; DIARRHEA; DIETARY INTAKE; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL INFECTION; GASTROINTESTINAL SYMPTOM; HEADACHE; HEALTH CARE COST; HUMAN; IRRITABLE COLON; ISCHEMIC COLITIS; MEDICAL RESEARCH; MENTAL DISEASE; MENTAL STRESS; META ANALYSIS; NAUSEA; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK FACTOR; SYSTEMATIC REVIEW; URTICARIA; VOMITING;

EID: 33846059947     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200727010-00002     Document Type: Review

References (59)

1. Andresen V, Camilleri M. Irritable bowel syndrome: recent and novel therapeutic approaches. Drugs 2006; 66 (8): 1073-88
2. Tack J, Fried M, Houghton LA, et al. Systematic review: the efficacy of treatments for irritable bowel syndrome: a European perspective. Aliment Pharmacol Ther 2006 Jul; 24 (2): 183-205
3. Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. Gastroenterol 2006 Apr; 130 (5): 1480-91
4. Gaynes BN, Drossman DA. The role of psychosocial factors in irritable bowel syndrome. Best Pract Res Clin Gastroenterol 1999 Oct; 13 (3): 437-52
5. Lea R, Whorwell PJ. New insights into the psychosocial aspects of irritable bowel syndrome. Curr Gastroenterol Rep 2003 Aug; 5 (4): 343-50
6. Adeniji OA, Barnett CB, Di Palma JA. Durability of the diagnosis of irritable bowel syndrome based on clinical criteria. Dig Dis Sci 2004 Apr; 49 (4): 572-4
7. Chang L. From Rome to Los Angeles: the Rome III criteria for the functional GI disorders [online]. Medscape 2006. Available from URL: http://www.medscape.com/viewarticle/533460 [Accessed 2006 Aug 21]
8. Drossman DA. The functional gastrointestinal disorders and the Rome II process. Gut 1999; 45 Suppl. II: II1-5
9. Manning AP, Thompson WG, Heaton KW, et al. Towards positive diagnosis of the irritable bowel. BMJ 1978 Sep; 2 (6138): 653-4
10. Thompson WG. The road to Rome. Gut 1999; 45 Suppl. II: II80-1
11. Ng C, Malcolm A, Hansen R, et al. distension technique influences the relationship between colonic and rectal hypersensitivity in irritable bowel syndrome. Neurogastroenterol Motil 2006 Mar; 18 (3): 206-10
12. Charapata C, Mertz H. Physician knowledge of Rome symptom criteria for irritable bowel syndrome is poor among non-gastroenterologists. Neurogastroenterol Motil 2006 Mar; 18 (3): 211-6
13. Jones R, Lydeard S. Irritable bowel syndrome in the general population. BMJ 1992 Jan; 304 (6819): 87-90
14. Hillilä MT, Färkkilä MA. Prevalence of irritable bowel syndrome according to different diagnostic criteria in a non-selected adult population. Aliment Pharmacol Ther 2004 Aug; 20 (3): 339-45
15. Mearin F, Badía X, Balboa A, et al. Irritable bowel syndrome prevalence varies enormously depending on the employed diagnostic criteria: comparison of Rome II versus previous criteria in a general population. Scand J Gastroenterol 2001 Nov; 36 (11): 1155-61
16. Xiong LS, Chen MH, Chen HX, et al. A population-based epidemiologic study of irritable bowel syndrome in South China: stratified randomized study by cluster sampling. Aliment Pharmacol Ther 2004 Jun; 19 (11): 1217-24
17. Hungin AP, Whorwell PJ, Tack J, et al. The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40,000 subjects. Aliment Pharmacol Ther 2003 Mar; 17 (5): 643-50
18. Hungin AP, Chang L, Locke GR, et al. Irritable bowel syndrome in the United States: prevalence, symptom patterns and impact. Aliment Pharmacol Ther 2005 Jun; 21 (11): 1365-75
19. Boyce PM, Talley NJ, Burke C, et al. Epidemiology of the functional gastrointestinal disorders diagnosed according to Rome II criteria: an Australian population-based study. Intern Med J 2006 Jan; 36 (1): 28-36
20. Kim HS, Rhee PL, Park J, et al. Gender-related differences in visceral perception in health and irritable bowel syndrome. J Gastroenterol Hepatol 2006 Feb; 21 (2): 468-73
21. ten Berg MJ, Goettsch WG, van den Boom G, et al. Quality of life of patients with irritable bowel syndrome is low compared to others with chronic diseases. Eur J Gastroenterol Hepatol 2006 May; 18 (5): 475-81
22. Donker GA, Foets M, Spreeuwenberg P. Patients with irritable bowel syndrome: health status and use of health care services. Br J Gen Pract 1999 Oct; 49 (447): 787-92
23. Faresjö A, Grodzinsky E, Foldevi M, et al. Patients with irritable bowel syndrome in primary care appear not to be heavy healthcare utilizers. Aliment Pharmacol Ther 2006 Mar; 23 (6): 807-14
24. Maxion-Bergemann S, Thielecke F, Abel F, et al. Costs of irritable bowel syndrome in the UK and US. Pharmacoeconomics 2006; 24 (1): 21-37
25. Drossman DA, Camilleri M, Mayer EA, et al. AGA technical review on irritable bowel syndrome. Gastroenterol 2002 Dec; 123 (6): 2108-31
26. Park M-I, Camilleri M. Is there a role of food allergy in irritable bowel syndrome and functional dyspepsia? A systematic review. Neurogastroenterol Motil 2006 Aug;18 (8): 595-607
27. Dapoigny M, Bellanger J, Bonaz B, et al. Irritable bowel syndrome in France: a common, debilitating and costly disorder. Eur J Gastroenterol Hepatol 2004 Oct; 16 (10): 995-1001
28. Zar S, Benson MJ, Kumar D. Food-specific serum IgG4 and IgE titers to common food antigens in irritable bowel syndrome. Am J Gastroenterol 2005 Jul; 100 (7): 1550-7
29. Zar S, Mincher L, Benson MJ, et al. Food-specific IgG4 antibody-guided exclusion diet improves symptoms and rectal compliance in irritable bowel syndrome. Scand J Gastroenterol 2005 Jul; 40 (7): 800-7
30. Mearin F, Badía X, Balboa A, et al. The RITMO Group. Predictive factors of irritable bowel syndrome improvement: 1-year prospective evaluation in 400 patients. Aliment Pharmacol Ther 2006 Mar; 23 (6): 815-26
31. Jailwala J, Imperiale TF, Kroenke K. Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomized, controlled trials. Ann Intern Med 2000 Jul; 133 (2): 136-47
32. Quartero AO, Meineche-Schmidt V, Muris J, et al. Bulking agents, antispasmodic and antidepressant medication for the treatment of irritable bowel syndrome. The Cochrane Library 2006, 3
33. Hussain Z, Quigley EM. Systematic review: complementary and alternative medicine in the irritable bowel syndrome. Aliment Pharmacol Ther 2006 Feb; 23 (4): 465-71
34. Langmead L, Rampton DS. Review article: complementary and alternative therapies for inflammatory bowel disease. Aliment Pharmacol Ther 2006 Feb; 23 (3): 341-9
35. Heading R, Bardhan K, Hollerbach S, et al. Systematic review: the safety and tolerability of pharmacological agents for treatment of irritable bowel syndrome - a European perspective. Aliment Pharmacol Ther 2006 Jul; 24 (2): 207-36
36. Evangelista S. Otilonium bromide: a selective spasmolytic for the gastrointestinal tract. J Int Med Res 1999; 27: 207-22
37. Otilonium bromide; product monograph. Excerpta Medica Italia 2002
38. Amenta F, Baroldi P, Ferrante F, et al. Autoradiographic localization of octylonium bromide binding sites in the rat gastrointestinal tract. Arch Int Pharmacodyn Ther 1991; 311: 5-19
39. Evangelista S, Giachetti A, Chapelain B, et al. Receptor binding profile of otilonium bromide. Pharmacol Res 1998 Aug; 38 (2): 111-7
40. Maggi CA, Manzini S, Meli A. Regional selectivity of calcium blockers at intestinal level. Archives Internationales de Pharmacodynamie et de Therapie 1985 Aug; 276 (2): 202-21
41. Santicioli P, Zagorodnyuk V, Renzetti AR, et al. Antimuscarinic, calcium channel blocker and tachykinin NK2 receptor antagonist actions of otilonium bromide in the circular muscle of guinea-pig colon. Naunyn-Schmiedebergs Archives of Pharmacology 1999 May; 359 (5): 420-7
42. Lindqvist S, Hernon J, Sharp P, et al. The colon-selective spasmolytic otilonium bromide inhibits muscarinic M3 receptor-coupled calcium signals in isolated human colonic crypts. Brit J Pharmacol 2002 Dec; 137 (7): 1134-42
43. Evangelista S, Cochet P, Bromet N, et al. A distribution study with 14C-otilonium bromide in the rat: evidence for selective tropism for large intestine after oral administration. Drug Metab Dispos 2000 Jun; 28 (6): 643-7
44. Czimmer J, Suto G, Kiraly A, et al. Otilonium bromide enhances sensory thresholds of volume and pressure in patients with irritable bowel syndrome. J Physiol (Paris) 2001 Jan-Dec; 95 (1-6): 153-6
45. 2+ channels and secretion in rat chromaffin cells. Eur J Pharmacol 1996 Mar; 298 (2): 199-205
46. Strege PR, Evangelista S, Lyford GL, et al. Otilonium bromide inhibits calcium entry through L-type calcium channels in human intestinal smooth muscle. Neurogastroenterol Motil 2004 Apr; 16 (2): 167-73
47. Sutton JA, Kilminster SG, Mould GP. The clinical pharmacology of single doses of otilonium bromide in healthy volunteers. Eur J Clin Pharmacol 1997; 52 (5): 365-9
48. Poynard T, Regimbeau C, Benhamou Y. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2001; 15: 355-61
49. Baldi F, Longanesi A, Blasi A, et al. Clinical and functional evaluation of the efficacy of otilonium bromide: a multicenter study in Italy. Ital J Gastroenterol 1991 Nov; 23 (8 Suppl. 1): 60-3
50. Battaglia G, Morselli-Labate AM, Camarri E, et al. Otilonium bromide in irritable bowel syndrome: a double-blind, placebo-controlled, 15-week study. Aliment Pharmacol Ther 1998 Oct; 12 (10): 1003-10
51. Glende M, Morselli-Labate AM, Battaglia G, et al. Extended analysis of a double-blind, placebo-controlled, 15-week study with otilonium bromide in irritable bowel syndrome. Eur J Gastroenterol Hepatol 2002 Dec; 14 (12): 1331-8
52. Kaushik A, Pursnani ML, Kar P. Multicenter phase III clinical trial of otilonium bromide in irritable bowel syndrome. Indian J Gastroenterol 2002 Mar-Apr; 21 (2): 85-6
53. Defrance P, Casini A. A comparison of the action of otilonium bromide and pinaverium bromide: study conducted under clinical control. Ital J Gastroenterol 1991 Nov; 23 (8 Suppl. 1): 64-6
54. Villagrasa M, Boix J, Humbert P, et al. Aleatory clinical study comparing otilonium bromide with a fiber-rich diet in the treatment of irritable bowel syndrome. Ital J Gastroenterol 1991 Nov; 23 (8 Suppl. 1): 67-70
55. Mollica G, Manno G. Otilonium bromide-diazepam in the treatment of the irritable colon: a controlled study versus otilonium bromide [Italian]. Clinical Terapeutica 1992 Aug; 141 (8): 129-34
56. Nedogoda SV, Parshev VV. Treatment of irritable bowel syndrome with dicetelium and Spasmomen [abstract]. Klinicheskaia Meditsina 2000; 78 (10): 42-6
57. Capurso L, Del Sette F, Ferrario F, et al. The otilonium bromide-benzodiazepine combination in the therapy of the irritable bowel syndrome [Italian]. Clinica Terapeutica 1992 Aug; 141 (8): 121
58. Ferrari A, Cavallero M, Spandre M, et al. Double-blind study of a new antimuscarinic, cimetropium bromide, in patients with irritable bowel syndrome. Clin Ther 1986; 8 (3): 320-8
59. Melani F. Otilonium bromide: clinical expert statement. Period between January 2001 and December 2005. 2006 Feb: 1-5. Data on file, Menarini S.p.A